GlassScriptPhysician profile
Prem Kumar Kittusamy
NPI 1568478840
$6,792.99
in general payments reported to CMS, 2019-2025
25 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $981 · 2021: $1,102 · 2022: $676 · 2023: $1,353 · 2024: $276 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Travel and Lodging: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.20 |
| Travel and Lodging | $643.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,833.15 | 2019-2024 | Barostim Neo System |
| Abbott Laboratories | $1,461.37 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $914.10 | 2023-2025 | Somatom Pro.Pulse, Biograph Mct X-4r, Magnetom Lumina |
| Medtronic Vascular, INC. | $606.45 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $319.25 | 2021-2025 | Venclose Maven Catheter |
| Nevro Corp. | $265.96 | 2019 | |
| Getinge USA Sales, LLC | $220.19 | 2023 | Cardiosave Hybrid, Type B Plug, Cardiohelp |
| Acist Medical Systems, INC. | $201.14 | 2019-2023 | |
| Boston Scientific Corporation | $154.45 | 2019-2021 | |
| Nuvasive, INC. | $152.59 | 2019 | |
| Biosense Webster, INC. | $135.53 | 2025 | Nuvision Ice Catheter |
| Telix Pharmaceuticals | $114.81 | 2025 | Illuccix |
| Medtronic, INC. | $90.04 | 2021 | |
| Impulse Dynamics (USA) INC. | $67.03 | 2022 | |
| Astellas Pharma US INC | $57.16 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.66 | 2019-2021 | |
| Amgen INC. | $24.69 | 2019-2020 | |
| Esperion Therapeutics, INC. | $21.59 | 2021 | |
| Ge Healthcare | $20.84 | 2025 | |
| Bardy Diagnostics, INC. | $18.38 | 2022 | |
| Edwards Lifesciences Corporation | $16.61 | 2021 | |
| Abbvie INC. | $16.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Pfizer INC. | $13.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Kittusamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.